Sanofi SNY and partner Regeneron REGN announced that the FDA has approved its blockbuster medicine Dupixent (dupilumab) for a new indication — moderate-to-severe atopic dermatitis (AD) or eczema in ...

Sanofi SNY and partner Regeneron REGN announced positive data from pivotal phase III study evaluating their blockbuster drug, Dupixent (dupilumab), to treat moderate-to-severe atopic dermatitis (“AD”) ...

June 7 (Reuters) - The U.S. Food and Drug Administration approved the use of Sanofi (SASY.PA), opens new tab and Regeneron Pharmaceuticals Inc's (REGN.O), opens new tab anti-inflammation drug Dupixent ...

ABBV's Rinvoq demonstrated strong efficacy to treat eczema. This put REGN's Dupixent in its cross hairs. Safety concerns could hurt Rinvoq's ability to take meaningful share away from Dupixent. REGN ...

Q. In a recent article about the challenges of treating eczema (atopic dermatitis), you described a number of over-the-counter treatments as well as modern prescription medicines. In particular, you ...

Sanofi and Regeneron’s Dupixent is already approved to treat eczema in kids as young as 6 years old—and it’s well on its way to becoming a $10 billion drug. Armed with a trial win in even younger ...

The European Commission (EC) approved Sanofi (NASDAQ:SNY) and Regeneron Pharmaceuticals' (NASDAQ:REGN) Dupixent to treat severe atopic dermatitis (eczema) in children aged six months to five years old ...

Rivals are closing in on Sanofi and Regeneron’s Dupixent. With AbbVie’s Rinvoq having already bested Dupixent in atopic dermatitis, Pfizer has now chalked up its own efficacy win over the blockbuster ...

(Reuters) -Regeneron Pharmaceuticals beat Wall Street estimates for third-quarter results on Tuesday, helped by strong demand for its eczema treatment, Dupixent, and cancer treatment Libtayo, sending ...

The first known lawsuit has now been filed against the makers of Dupixent (dupilumab), alleging that the popular eczema and asthma drug caused or accelerated a deadly form of lymphoma. Filed in ...